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Aims Quantitative real-time RT-PCR (RT-qPCR) has become the method of choice for mRNA quantification, but re-
quires an accurate normalization based on the use of reference genes showing invariant expression across various
pathological conditions. Only few data exist on appropriate reference genes for the human heart. The objective of
this study was to determine a set of suitable reference genes in human atrial and ventricular tissues, from right and
left cavities in control and in cardiac diseases.
....................................................................................................................................................................................................
Methods
and results
We assessed the expression of 16 reference genes (ACTB, B2M, GAPDH, GUSB, HMBS, HPRT1, IPO8, PGK1, POLR2A,
PPIA, RPLP0, TBP, TFRC, UBC, YWHAZ, 18S) in tissues from: right and left ventricles from healthy controls and heart
failure (HF) patients; right-atrial tissue from patients in sinus rhythm with (SRd) or without (SRnd) atrial dilatation,
patients with paroxysmal (pAF) or chronic (cAF) atrial fibrillation or with HF; and left-atrial tissue from patients in
SR or cAF. Consensual analysis (by geNorm and Normfinder algorithms, BestKeeper software tool and comparative
delta-Ct method) of the variability scores obtained for each reference gene expression shows that the most stably
expressed genes are: GAPDH, GUSB, IPO8, POLR2A, and YWHAZ when comparing either right and left ventricle or ventri-
cle from healthy controls and HF patients; GAPDH, IPO8, POLR2A, PPIA, and RPLP0 when comparing either right and left
atrium or right atria from all pathological groups. ACTB, TBP, TFRC, and 18S genes were identified as the least stable.
....................................................................................................................................................................................................
Conclusions The overall most stable reference genes across different heart cavities and disease conditions were GAPDH, IPO8,
POLR2A and PPIA. YWHAZ or GUSB could be added to this set for some specific experiments. This study should
provide useful guidelines for reference gene selection in RT-qPCR studies in human heart.
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1. Introduction
The four chambers of a healthy heart are characterized by specific ge-
netic, anatomic, metabolic, physiologic, and electric features. For example,
right (RV) and left ventricles (LVs) have different mass, volume, morphol-
ogy and pressures.1,2 Morphological differences also exist between the
right and left atrium.3 Additionally, there are chamber-specific differences
in electrophysiological properties4,5 including different action potential
parameters due to specific expression patterns and function of ion chan-
nels.6,7 Accordingly, regional heterogeneity between left and right heart
chambers also exists for the expression of many genes,6,8–13
microRNAs,14 as well as frequently used housekeeping genes.15
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Atrial fibrillation (AF) and heart failure (HF) are common cardiac dis-
orders associated with significant morbidity, mortality, and a growing
public health cost.16–18 AF- and HF-related remodelling processes are as-
sociated with profound genetic, structural and functional alterations19–22
which differ between left and right heart chambers.23–25 Although AF is
considered to predominantly occur in the left atrium, recent data by
Karapinar et al.26 showed profound changes in the electrical properties
in the right atrium of paroxysmal atrial fibrillation (pAF) patients pointing
to specific remodelling in the right atrium of these patients. b-adreno-
ceptor (b-AR) blockers are a well-established therapy for HF, but the
b-AR response may differ between left and right ventricles.5
Although there is clear evidence that altered gene transcription con-
tributes to the pathological cardiac remodelling leading to AF or HF, the
precise mechanisms of altered gene transcription are not completely un-
derstood. In this context, gene expression profiling of the human heart
has become an essential step to study in-depth the molecular regulatory
networks that underlie chamber-specific differences between healthy
and diseased hearts. Quantitative real-time polymerase chain reaction
(RT-qPCR) is the most sensitive and accurate technique to simulta-
neously amplify and quantify gene expression by measuring the incre-
ment of fluorescence in each PCR cycle. However, PCR readouts need
an accurate normalization with internal reference genes whose expres-
sion has to be stable27 and independent of the experimental groups or
remodelling processes. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), 18S ribosomal RNA (18S), b-actin (ACTB) or b2-microglobulin
(B2M) have been used extensively as reference genes in RT-qPCR for
heart samples.28–31 Yet, a number of studies have demonstrated that the
expression of some of these classically used housekeeping genes vary sig-
nificantly according to the species, experimental model, disease condi-
tion, tissue type, etc.30,32–35 In human heart, a recent study used human
HF samples to select stable housekeeping genes for normalizing gene ex-
pression data between HF left and right ventricles,36 but no optimal set
of reference genes has been identified so far for normalizing gene ex-
pression data across right and left atria or for comparing the different
cardiac cavities in healthy and diseased states.
The aim of this study was to assess the expression of 16 classical genes
used as housekeeping genes (ACTB, B2M, GAPDH, b-D-glucuronidase
(GUSB), hydroxymethylbilane synthase (HMBS), hypoxanthine phos-
phoribosyltransferase 1 (HPRT1), importin 8 (IPO8), phosphoglycerate
kinase 1 (PGK1), RNA polymerase II subunit A (POLR2A), peptidylprolyl
isomerase A (PPIA), ribosomal protein lateral stalk subunit P0 (RPLP0),
TATA box binding protein (TBP), transferrin receptor (TFRC), ubiquitin
C (UBC), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase ac-
tivation protein zeta (YWHAZ) and 18S ribosomal RNA (18S)) and to se-
lect a set of reference genes that can be reliably used for normalization
of RT-qPCR experiments in atrial and ventricular tissues from left and
right cavities of healthy subjects or patients with AF or HF. A combined
analysis of the results using GeNorm35 and NormFinder37 algorithms,
the BestKeeper38 software tool and the comparative Delta-Ct method39
was performed to strengthen and validate the selection of the top-
ranking reference genes in order to propose an optimal set of reference
genes across the different heart cavities and cardiac diseases.
2. Methods
2.1 Selection of candidate reference genes
For this study, we used the TaqMan Human Endogenous Control Arrays
(Applied Biosystems, Life Technologies, France) which contain
commonly used housekeeping genes that exhibit minimal differential ex-
pression across many different tissues: ACTB, B2M, GAPDH, GUSB, HMBS,
HPRT1, IPO8, PGK1, POLR2A, PPIA, RPLP0, TBP, TFRC, UBC, YWHAZ, 18S.
Each array includes three replicates per gene and per sample.
2.2 Human tissue samples used for
selection of reference genes
A total of 44 human heart tissue samples were collected from a total of
36 patients undergoing cardiac surgery either at the Institut Hospitalier
Jacques Cartier, Massy, France, at the Cardiac Surgery Department,
Hospital de la Santa Creu i Sant Pau, Universitat Auto`noma de
Barcelona, Spain, at the Abt. Kardiologie und Pneumologie, Georg-
August-Universitaet Go¨ttingen, Germany, or at the Department of
Pharmacology and Pharmacotherapy, University of Szeged, Hungary. 28
specimens of atrial appendages were obtained from 28 patients sub-
jected to atrial cannulation for extracorporal circulation. Permission to
use atrial tissue samples that would normally be discarded during cardiac
surgery was obtained from each patient. Healthy control (CT) and failing
(HF) RV and LV tissues were collected respectively from 4 healthy and 4
failing explanted human hearts at the time of the extraction. All samples
were immediately frozen in liquid nitrogen and stored at -80 C. Details
regarding the clinical characteristics of the patients and their treatments
are shown in Table 1.
The study was conducted in accordance with the Declaration of
Helsinki principles, and approved by the Ethical Committees of our insti-
tutions. All protocols for obtaining human cardiac tissue were approved
by the Ethical Committees and informed consent was obtained before
cardiac surgery.
2.3 Human tissue samples used for
validation of the preselected reference
genes
A selection of the above described human heart samples was used to
measure expression of two target genes, protein phosphatase 2 catalytic
subunit alpha isoform (PPP2CA) in atrial samples and adenylate cyclase
type V (ADCY5) in ventricular samples, and validate the proposed set of
reference genes. Table 1 summarizes the clinical characteristics of the
subset of patients used in this study. Thus, a total of 15 atrial samples
from patients subjected to atrial cannulation during surgery and 7 ven-
tricular samples from explanted human hearts were used for this part of
the study.
2.4 RNA isolation and cDNA synthesis
Frozen tissue samples were weighed and placed in pre-cooled tubes
containing TRIzol reagent (Invitrogen, Life Technologies, France) and
rapidly subjected to automated grinding in a Bertin Precellys 24 (Bertin
Technologies, France). Total RNA extraction was carried out using stan-
dard procedure according to the manufacturer’s instructions. RNA con-
centration and purity were evaluated by optical density (OD)
(Biophotometer, Eppendorf, BioServ, France) and the integrity of the
RNA samples were analyzed on a Bioanalyzer 2100 with the RNA6000
Nano Labchip Kit (Agilent Technologies, Santa Clara, CA, USA). The
RNA integrity number (RIN) was calculated by the instrument software.
First strand cDNA synthesis was performed from 2lg of total RNA with
random primers and MultiScribe Reverse Transcriptase according to the
provided protocol (Applied Biosystems, Life Technologies, France). To
minimize intergroup variations, samples of each experimental group
were processed simultaneously.
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2.5 Real-time qPCR and quantification
Real-time PCR assays were performed using TaqMan 384-well microflui-
dic card technology from Applied Biosystems (TaqMan Array Card or
TAC, Life Technologies, France) and the TaqMan Human Endogenous
Control Panel. These TAC were designed to study the expression stabil-
ity of 16 potential reference genes (Table 2). As mentioned earlier, the
16 reference genes were chosen by their common use as endogenous
control genes. Each PCR reaction was performed on 4 ng of cDNA in a
volume of 1 ml. The thermal cycling conditions for PCR amplification on
TAC were 10 min at 94.5 C, followed by 40 cycles of 30 s at 97 C and
1 min at 59.7 C, on a ABI-Prism 7900HT Sequence Detection
Instrument (Applied Biosystems, Life Technologies, France). Each
TaqMan assay was previously validated by Applied Biosystems and the
efficiency of amplification was certified to be superior to 90% by the sup-
plier. Experiments were performed in triplicate for each sample.
2.6 Evaluation of candidate reference genes
Reference gene expression variability was evaluated by using a combined
analysis of geNorm, Normfinder, BestKeeper and Delta-Ct method. In a
real time PCR assay a positive reaction is detected by accumulation of a
fluorescent signal. The Ct (cycle threshold) is defined as the number of
cycles required for the fluorescent signal to reach a define threshold.
..................... .................................................. .........................................................................................
..............................................................................................................................................................................................................................
Table 1 Clinical characteristics of patients
Age media
6 S.E.M.
Gender (n) Surgery (n) Treatment regimens (n)
F M AVS MVS CABG CTr CD b-blockers Calcium
antagonists
ACE
inhibitors
Diuretics Statins
RA SRnd* 64 ± 5.8 1 3 1 0 4 0 0 2 0 3 0 1
SRd* 69 ± 6.5 3 1 1 1 1 0 0 2 1 3 1 1
pAF* 78 ± 3.6 0 4 2 0 3 0 0 3 0 1 1 1
cAF* 73 ± 3.1 0 4 2 1 2 0 0 2 1 2 3 0
HF 71 ± 5.6 0 4 1 2 2 0 0 2 0 2 2 3
LA SRnd 69 ± 3.8 0 4 2 0 1 0 0 1 1 2 2 1
AFc 69 ± 2 2 2 2 4 1 0 0 3 0 2 3 0
RV* and LV CT* 44 ± 4.6 2 2 0 0 0 0 4 0 0 0 0 0
HF* 59 ± 3.8 2 2 0 0 0 4 0 3 0 4 4 2
AVS, aortic valve surgery; MVS, mitral valve surgery; CABG, coronary artery bypass graft; CTr, cardiac transplantation; CD, cerebral death. Some included patients were submitted
to valve surgery and coronary artery bypass graft surgery. RA, right atrium; LA, left atrium; RV, right ventricle; and LV, left ventricle. SRnd, Sinus Rhythm without atrium dilatation;
SRd, Sinus Rhythm with atrium dilatation; pAF, paroxysmal atrial fibrillation; cAF, chronic atrial fibrillation; HF, Heart Failure and CT, Healthy controls. *indicate the samples that
were used to measure expression of two target genes.
..............................................................................................................................................................................................................................
Table 2 TaqMan assays used for RT-qPCR amplification
Gene symbol Gene name Applied Biosystems assay TaqMan probe exons PCR product size (bp)
ACTB b-actin Hs99999903_m1 1 171
POLR2A RNA polymerase II subunit A Hs00172187_m1 1-2 61
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein zeta
Hs00237047_m1 1-2 70
PGK1 phosphoglycerate kinase 1 Hs99999906_m1 4-5 75
PPIA peptidylprolyl isomerase A (cyclophilin A) Hs99999904_m1 4 98
GAPDH glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1 3 122
IPO8 importin 8 Hs00183533_m1 16-17 71
HMBS hydroxymethylbilane synthase Hs00609297_m1 1-2 64
HPRT1 hypoxanthine phosphoribosyltransferase 1 Hs99999909_m1 6-7 100
GUSB b-D-glucuronidase Hs99999908_m1 11-12 81
B2M b-2-microglobulin Hs99999907_m1 2-3 75
RPLP0 ribosomal protein lateral stalk subunit P0 Hs99999902_m1 3 105
TBP TATA box binding protein Hs99999910_m1 7 127
TFRC transferrin receptor Hs99999911_m1 14 105
UBC ubiquitin C Hs00824723_m1 1-2 71
18S eukaryotic 18S ribosomal RNA Hs99999901_s1 1 187
PPP2CA protein phosphatase 2, catalytic subunit, alpha isozyme Hs00427260_m1 6-7 77
ADCY5 Adenylate cyclase type V Hs00766287_m1 16-17 72
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Ct levels are inversely proportional to the amount of target nucleic acid
in the sample. Ct is specific to the expression of one gene whereas Delta
Ct shows the difference of expression between two genes. This DCt ap-
proach can be used to study the stability of candidate housekeeping
genes by comparing the relative expression of ‘pairs of genes’ within
each sample.39 GeNorm algorithm ranks the candidate reference genes
by an expression stability measurement called M-value which is the aver-
age pairwise variation of a particular gene with all the other reference
genes.35 The most stable genes are the ones with the lowest M-value.
NormFinder algorithm also ranks the set of candidate normalization
genes according to their expression stability and it can also take informa-
tion of samples grouping to define intra- and inter-group variations for
each candidate reference gene. The result is an optimum rank of refer-
ence genes.37 BestKeeper determines the most stably expressed genes
based on the coefficient of correlation to the BestKeeper Index, which is
the geometric mean of the candidate reference gene Ct values.
BestKeeper also calculates the standard deviation (SD) so that the best
reference genes are those with the lowest SD and coefficient of variation
(CV) based on the Ct values of all candidate reference genes.38
Following these four analyses, each candidate reference gene obtained a
specific ranking value. A consensual analysis was finally performed by the
calculation of the geometric mean of the four ranking values for each
gene leading to a consensus variability score for each reference gene.40
PPP2CA and ADCY5 were selected to confirm the appropriate refer-
ence genes pool by measuring their relative expression levels. TaqMan
Array Cards were also used to perform real-time PCR experiments un-
der the same experimental conditions and with the subset of samples in-
dicated in Table 1. For each group, an average Ct was calculated. The
average Ct of the control groups, Sinus Rhythm without atrium dilatation
(SRnd) and CT, was used as calibrator for the atria and ventricles, re-
spectively. The determination of the relative gene expression ratio was
achieved using the DDCt method, i.e. it is calculated by referring to the
calibrator and normalized by a housekeeping gene or the geometric
mean of a set of stable housekeeping genes.
2.7 Statistical analysis
Results are expressed as mean ± SEM. For statistical evaluation of two
sets of data Mann-Whitney test was used. Kruskal-Wallis test was used
for multiple comparisons to evaluate the significance between groups. A
difference was considered statistically significant when P < 0.05.
3. Results
3.1 Total RNA sample concentration and
quality
Total RNA content, 260/280 nm OD ratio and RIN obtained in the four
human cardiac cavities under normal or pathological conditions are sum-
marized in Table 3. There were no differences in RNA content between
the groups neither in the atria nor in the ventricles, or between atria and
ventricles. The quality control parameters for human total RNA samples
were similar regardless of human heart tissue sample collection, with no
difference between the groups. The 260/280 nm OD ratios appeared
relatively low (range of 1.5–1.7), but the RIN values were consistent and
comparable within different heart cavities and cardiac diseases, with an
overall average of 7.1.
3.2 Selection of candidate reference genes
Using RT-qPCR, we evaluated simultaneously the expression of 16 refer-
ence gene candidates on the 44 human heart tissue samples (Table 1).
Figure 1 illustrates the variation in candidate reference gene abundance
across all samples. For sake of clarity, the reference genes are ordered
by their respective abundance. This first analysis showed as expected the
dominance of 18S rRNA transcripts compared with the other reference
genes. The other reference genes were separated into two groups ac-
cording to their abundance: (i) ACTB, B2M, GAPDH, PGK1, PPIA, RPLP0,
and UBC, with a median Ct value from 17 to 21; (ii) GUSB, HMBS, HPRT1,
IPO8, POLR2A, TBP, TFRC, and YWHAZ with a median Ct value from 23 to
27. We found that some genes had a high variability in expression, e.g.
18S, ACTB, B2M, TBP, and TFRC, whereas others were more stable, e.g.
HMBS and POLR2A. So, based on their relative abundance and steady ex-
pression across all the samples, a pre-selection of candidate reference
genes could be considered.
We then performed a combined statistical analysis of the candidate ref-
erence gene variability by taking into account the results from the
geNorm and NormFinder algorithms, the comparative Delta-Ct method
and the BestKeeper software tool. The overall rank order of the most sta-
ble reference genes is shown in Table 4 for different comparisons across
heart cavities and disease conditions. We summarized these results using a
gene oblong chart to illustrate more easily the set of five reference genes
that is the most suitable for normalizing gene expression data according to
the considered heart cavity and cardiac disease (Figure 2).
Concerning the right atrium, a first analysis including 20 patients in SR
or AF and HF brought out the following set of five reference genes:
POLR2A, GAPDH, PPIA, IPO8, RPLP0. This set of reference genes varied ac-
cording to the progression from SR [SRnd or sinus rhythm with atrium
(SRd)] to pAF and chronic atrial fibrillation (cAF), respectively, or de-
pending on the type of cardiac pathology (AF vs. HF). The optimal set of
reference genes for comparison of RA-SRnd vs. SRd appeared to be
RPLP0, PPIA, POLR2A, B2M, and HMBS. RPLP0, together with PGK1,
GAPDH, IPO8, and HMBS appear to represent a good choice as reference
genes when comparing SRnd with pAF samples. In contrast, when the
comparison includes cAF samples, RPLP0 is no more a reliable option; so,
the best selection of reference genes includes POLR2A, PPIA, GAPDH,
......................................... .................
......................................................................................................
Table 3 Quality control of RNA samples
n RNA content
(mg/mg)
260 nm/280 nm OD ratio RIN
Mean SD Mean SD
RA SRnd 4 0.49 ± 0.01 1.70 0.13 6.9 0.81
SRd 4 0.55 ± 0.06 1.63 0.16 7.2 0.29
pAF 4 0.37 ± 0.05 1.57 0.11 6.8 0.54
cAF 4 0.44 ± 0.05 1.67 0.14 6.9 0.28
HF 4 0.52 ± 0.16 1.66 0.18 7.5 0.15
LA
SR 4 0.43 ± 0.09 1.68 0.07 6.7 0.61
cAF 4 0.43 ± 0.10 1.61 0.13 6.7 0.80
RV
CT 4 0.45 ± 0.22 1.58 0.19 7.1 0.49
HF 4 0.65 ± 0.06 1.72 0.09 7.6 0.85
LV
CT 4 0.71 ± 0.04 1.54 0.06 6.9 1.43
HF 4 0.70 ± 0.04 1.72 0.09 7.6 0.80
RA, right atrium; LA, left atrium; RV, right ventricle; and LV, left ventricle. SRnd,
sinus rhythm without atrium dilatation; SRd, sinus rhythm with atrium dilatation;
pAF, paroxysmal atrial fibrillation; cAF, chronic atrial fibrillation; HF, heart failure;
and CT, Healthy controls.
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..HPRT1, and PGK1. Based on these results, we propose GAPDH, IPO8,
POLR2A, PPIA, and RPLP0 as an optimal set of reference genes to perform
all the comparisons in the right atrium.
Regarding gene expression studies in all heart cavities, the results
point to one common reference gene, POLR2A, among the top five for
the RA/LA, RV/LV and A/V comparisons. GAPDH, GUSB, IPO8, and PPIA
can be added to POLR2A which should warrant a minimal set of three to
four reference genes for normalization of the RT-qPCR data.
GUSB appears as an appropriate reference gene when comparing ven-
tricles in normal and pathological states. IPO8, PGK1, HMBS, and POLR2A
can be added to GUSB when comparing left and right ventricles. For stud-
ies of HF in LV samples, the same genes can be used but YWHAZ could be
preferred over POLR2A. However, to elucidate changes in gene expres-
sion related to HF in RV, GAPDH, POLR2A, GUSB, HPRT1, and PPIA repre-
sent the best set of reference genes. Altogether, a minimum of three
reference genes among GAPDH, GUSB, IPO8, POLR2A and YWHAZ would
provide a useful set to compare normal and failing ventricular cavities.
Among the 16 reference genes studied for their expression stability in
healthy and pathological human heart cavities, our data also show that
four genes should not be used for normalization: 18S, TBP, TFRC, and
ACTB. Indeed, in each comparison presented in Table 4, the two least sta-
ble genes belong to this set.
Finally, for a study comparing all cardiac chambers under normal and
pathological conditions, a good set of reference genes should be:
GAPDH, IPO8, POLR2A, PPIA, and YWHAZ or GUSB. Depending on the
groups or conditions compared, this set of reference genes should lead
to a minimal set of two to four reference genes to be used for normaliza-
tion of RT-qPCR data.
3.3 Validation of the set of reference genes
We then tested our normalization strategy by comparing RT-qPCR data
normalized to either 18S or to our final set of reference genes (GAPDH,
IPO8, POLR2A, PPIA, and YWHAZ) for two genes of interest: PPP2CA in
the right atrium from SR (SRnd or SRd), pAF and cAF patients; ADCY5 in
the right ventricle from CTs and HF patients (Figure 3).
A large and statistically significant difference in PPP2CA gene expres-
sion was found between cAF and the other groups when using 18S as
reference gene for normalization (Figure 3A) but not when using the set
of reference genes for normalization (Figure 3B). Since earlier studies us-
ing a-actin as reference gene for the RT-qPCR experiments showed no
change in PPP2CA gene expression in cAF,41,42 this validates the choice of
the set of reference genes from our study when comparing human atrial
tissues.
Similarly, when comparing HF vs. CT ventricular samples, a significant
increase in the expression level of ADCY5 was found in HF when normal-
ization was made with the selected set of reference genes (Figure 3D) but
the expression appeared unchanged between CT and HF samples when
normalization was based only on 18S (Figure 3C). A similar absence of
variation of ADCY5 mRNA between CT and HF was found in a pig model
when normalizing to the expression of 18S.43 In another study in dog
heart, a decrease in ADCY5 expression was observed in HF when nor-
malizing to the expression of ACTB,44 one of least stable reference gene
identified in our study. In contrast, an elevation of ADCY5 mRNA levels
was found by Northern analysis in human ventricular samples from pa-
tients with HF when normalizing with GAPDH,45 one of the best stable
reference gene selected in this study. This validates the choice of the set
of reference genes from our study when comparing human ventricular
samples.
4. Discussion
In this study, we provide a detailed analysis of reference genes in cardiac
tissues from different regions (right and left atria and ventricles) of the
heart of patients with different pathological conditions. We show that
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Figure 1 Variation in candidate reference gene expression in all tissue heart samples. Box-and-whisker plots showed the Ct values of each reference gene
analyzed in a total of 44 heart tissues from 36 patients. Boxes indicated median (Q2) and quartiles first and third (Q1 and Q3) and whiskers corresponded
to the minimum and maximum values.
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there is not one universal gene being appropriate to obtain a correct
normalization for all types of human cardiac tissues. Based on a com-
bined statistical analysis, we propose a set of most stable reference genes
to be used when comparing RT-qPCR data obtained from healthy or dis-
eased human cardiac tissues.
A considerable number of studies used 18S or ACTB genes as internal
controls for RT-qPCR analysis in heart samples. As shown earlier,46 we
found using three different algorithms (GeNorm, NormFinder, and
Delta-Ct) that these genes, along with TBP and TFRC, are the two genes
with the least stable expression in all our groups of samples (Table 4).
Accordingly, using one of these single commonly used reference genes
to compare the level of expression of two genes of interest, PPP2CA and
ADCY5, in healthy and diseased cardiac tissues led to misleading results,
while on the contrary, using the geometric mean of our set of reference
genes for normalization of the RT-qPCR data led to results that were
consistent with the literature (Figure 3).
The choice of appropriate reference genes is, thus, of crucial impor-
tance when comparing RT-qPCR data from mRNA collected from differ-
ent human heart samples. Although this issue has been addressed in a
number of earlier studies, none of them provided a thorough and sys-
tematic analysis as performed here. We analysed 16 reference gene can-
didates and compared their level of expression and degree of stability in
the four heart chambers and in control and diseased states. We found
that GAPDH, IPO8, POLR2A, PPIA, and YWHAZ or GUSB provide an opti-
mal set of genes to be used to normalize data in human heart tissue
samples. PPIA has been shown earlier as an appropriate internal control
gene in studies with atrial,47 right ventricular15,47 and LV samples from
healthy donors15,48 and from HF patients.47,49 Martino et al.47 also con-
firmed our findings about the use of HPRT1 as a reference gene in human
atria and the use of GAPDH in right ventricle. These results are also in ac-
cordance with the study of Svobodova´ et al.50 performed in pig heart.
Veseneti et al.51 showed that HMBS, HPRT1 and YWHAZ are reliable ref-
erence genes when working with right or ischemic LV samples.
However, together with Koppelkamm et al.,46 they identified TBP as an
appropriate reference gene when studying LV samples, while our data in-
dicate that expression of this gene is highly variable (Table 4). However,
TBP may be suitable as a reference gene only in combination with HMBS
and HPRT1, and only in the remote region of the left ventricle in rats.51
On the other hand, Koppelkamm et al. recommended the use of TBP in
combination of at least three other reference genes, including HMBS, in
post mortem cardiac muscle tissue with RIN mean values of 3.9.46 Other
studies,49,52 predominantly performed in left ventricles, showed that
GAPDH is not a good reference gene. Our study shows that GAPDH ex-
pression is more stable in right than LV samples, and it can also be used
as a reference gene in healthy and diseased atria and for comparison be-
tween atrial and ventricular tissues (Figure 2, Table 4). This is in agree-
ment with recent works showing that GAPDH has the highest expression
stability between the tested genes in both HF and healthy heart samples
in right and left ventricle.36,53 POLR2A was ranked top three by the geo-
metric consensus method for most atrial and RV studies, while IPO8 and
GUSB were the most preserved reference genes in LV samples. This
highlights the importance of choosing the most appropriate internal ref-
erence gene when studying chamber-specific differences in gene expres-
sion. To the best of our knowledge, IPO8 or GUSB have never been used
as reference genes in human heart samples.
An important aspect to take into consideration is the quality of the
mRNA samples. It was shown earlier that the RIN values are lower and
the variation in the RT-qPCR much larger in human than in rodent heart
samples,49 possibly due to differences in harvesting times or a conse-
quence of the type and duration of the diseased condition. Thus, RNA
integrity was carefully checked in our samples and the RIN values were
consistent and comparable within the different heart cavities and cardiac
diseases. Another important aspect is the method of analysis used to
evaluate the variability in gene expression. Indeed, we compared the ex-
pression variability for the 16 reference gene candidates using four differ-
ent methods of analysis (geNorm, Normfinder, BestKeeper and
comparative delta-Ct) and found that each method could give a different
ranking of the 16 genes (Table 4). This shows that using a single method
of analysis to evaluate the relative expression of a gene cannot be rec-
ommended because this could lead to false-positive or false-negative re-
sults. We propose to use at least three methods of analysis and to
calculate a geometric mean of the rankings as used here.
In conclusion, when performing RT-qPCR analysis on different
samples obtained from different cardiac tissues and/or diseased
states, we recommend (i) to use a normalization based on a set of
three to five stable reference genes rather than on a single gene, and
(ii) to use at least three methods of analysis of gene variability and cal-
culate a geometric mean of the rankings to select the most robust set
of reference genes. We validated this strategy in human heart using
samples obtained from four cardiac chambers and up to five different
pathophysiological conditions. Based on our combined results, we
recommend the use of GAPDH, IPO8, POLR2A, PPIA, and YWHAZ or
GUSB as reference genes for RT-qPCR when performing studies with
human heart samples.
Figure 2 Consensual statistical analysis of variation in candidate ref-
erence gene expression in different heart cavities and health conditions.
Gene oblong chart illustrating an integrated model of the best gene se-
lection in different human heart cavities and diseases. Gene names indi-
cated in bold are part of the most appropriate selection of 5 reference
genes for all comparisons.
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Table 4 Analysis of reference gene expression variability
Genorm Normfinder Delta-Ct BestKeeper Consensus
Genes Stability value Genes Stability value Genes SD Genes SD Genes Geometric mean
of ranking values
RA SR/AF-HF (n = 8/12) POLR2A 0.241 POLR2A 0.136 POLR2A 0.38 HMBS 0.17 POLR2A 1.50
GAPDH 0.241 RPLP0 0.196 IPO8 0.41 PPIA 0.22 GAPDH 3.13
IPO8 0.251 IPO8 0.197 PPIA 0.41 B2M 0.28 PPIA 3.60
PGK1 0.257 PPIA 0.223 GAPDH 0.42 GAPDH 0.28 IPO8 3.66
HPRT1 0.261 HPRT1 0.241 RPLP0 0.42 POLR2A 0.30 RPLP0 5.61
UBC 0.276 GAPDH 0.245 HPRT1 0.43 GUSB 0.31 HMBS 6.04
PPIA 0.290 PGK1 0.262 PGK1 0.44 UBC 0.32 PGK1 6.29
B2M 0.302 UBC 0.269 B2M 0.44 PGK1 0.35 B2M 6.45
RPLP0 0.314 B2M 0.270 UBC 0.44 ACTB 0.36 HPRT1 6.51
GUSB 0.325 GUSB 0.277 GUSB 0.45 IPO8 0.36 UBC 7.42
HMBS 0.333 HMBS 0.314 HMBS 0.47 RPLP0 0.42 GUSB 8.80
YWHAZ 0.358 YWHAZ 0.415 YWHAZ 0.54 HPRT1 0.46 ACTB 11.86
ACTB 0.384 ACTB 0.459 ACTB 0.57 TFRC 0.52 YWHAZ 12.47
18S 0.422 18S 0.580 18S 0.68 YWHAZ 0.59 18S 14.24
TFRC 0.457 TFRC 0.618 TFRC 0.71 18S 0.62 TFRC 14.47
TBP 0.499 TBP 0.725 TBP 0.80 TBP 0.73 TBP 16.00
RA SRnd/SRd (n = 4/4) POLR2A 0.073 RPLP0 0.083 RPLP0 0.30 HMBS 0.15 RPLP0 1.73
RPLP0 0.073 PPIA 0.133 PPIA 0.32 PPIA 0.24 PPIA 2.21
PPIA 0.153 POLR2A 0.139 POLR2A 0.32 B2M 0.25 POLR2A 2.82
B2M 0.173 TFRC 0.157 B2M 0.33 ACTB 0.27 B2M 4.12
IPO8 0.189 GAPDH 0.157 GAPDH 0.33 GUSB 0.28 HMBS 5.48
GAPDH 0.198 B2M 0.173 UBC 0.34 UBC 0.30 GAPDH 6.22
TRFC 0.217 UBC 0.174 IPO8 0.34 IPO8 0.33 UBC 6.70
UBC 0.226 IPO8 0.185 TFRC 0.35 POLR2A 0.33 IPO8 6.88
HMBS 0.237 HPRT1 0.223 HPRT1 0.37 GAPDH 0.34 TFRC 7.05
HPRT1 0.253 HMBS 0.275 HMBS 0.39 RPLP0 0.34 GUSB 9.64
PGK1 0.266 PGK1 0.290 PGK1 0.40 TFRC 0.36 ACTB 10.05
GUSB 0.279 GUSB 0.295 GUSB 0.41 PGK1 0.38 HPRT1 10.32
ACTB 0.306 YWHAZ 0.436 YWHAZ 0.52 18S 0.49 PGK1 11.24
YWHAZ 0.334 ACTB 0.458 ACTB 0.53 HPRT1 0.49 YWHAZ 13.73
18S 0.365 18S 0.523 18S 0.59 YWHAZ 0.61 18S 14.47
TBP 0.412 TBP 0.697 TBP 0.74 TBP 0.71 TBP 16.00
RA SRnd/pAF (n = 4/4) IPO8 0.082 PGK1 0.102 RPLP0 0.34 HMBS 0.16 RPLP0 2.06
RPLP0 0.082 RPLP0 0.105 GAPDH 0.34 GUSB 0.19 PGK1 3.20
POLR2A 0.123 GAPDH 0.118 PGK1 0.35 B2M 0.21 GAPDH 3.46
GAPDH 0.161 IPO8 0.120 IPO8 0.35 PPIA 0.23 IPO8 3.64
PGK1 0.190 POLR2A 0.150 POLR2A 0.36 ACTB 0.24 HMBS 4.60
B2M 0.210 B2M 0.182 B2M 0.37 GAPDH 0.28 B2M 5.05
PPIA 0.234 HPRT1 0.228 HMBS 0.40 PGK1 0.28 POLR2A 5.23
HMBS 0.248 HMBS 0.230 HPRT1 0.41 POLR2A 0.34 GUSB 6.50
GUSB 0.261 UBC 0.261 GUSB 0.42 RPLP0 0.34 PPIA 7.27
UBC 0.275 PPIA 0.275 PPIA 0.42 UBC 0.34 UBC 9.43
HPRT1 0.286 GUSB 0.276 UBC 0.42 18S 0.37 HPRT1 9.64
TFRC 0.315 YWHAZ 0.432 TFRC 0.53 IPO8 0.37 ACTB 11.40
YWHAZ 0.341 18S 0.433 YWHAZ 0.54 TFRC 0.37 TFRC 12.47
18S 0.364 TFRC 0.444 18S 0.54 HPRT1 0.47 YWHAZ 13.21
ACTB 0.388 ACTB 0.529 ACTB 0.59 YWHAZ 0.56 18S 13.49
TBP 0.458 TBP 0.918 TBP 0.95 TBP 0.85 TBP 16.00
RA SRnd/cAF (n = 4/4) GAPDH 0.138 POLR2A 0.101 POLR2A 0.37 HMBS 0.15 POLR2A 2.14
PPIA 0.138 HPRT1 0.140 PPIA 0.37 UBC 0.20 PPIA 2.34
POLR2A 0.195 PGK1 0.153 HPRT1 0.38 PPIA 0.21 GAPDH 3.60
HPRT1 0.217 IPO8 0.168 PGK1 0.39 GAPDH 0.25 HPRT1 4.03
Continued
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Table 4 Continued
Genorm Normfinder Delta-Ct BestKeeper Consensus
Genes Stability value Genes Stability value Genes SD Genes SD Genes Geometric mean
of ranking values
IPO8 0.225 PPIA 0.168 IPO8 0.39 B2M 0.26 PGK1 4.90
PGK1 0.235 RPLP0 0.225 GAPDH 0.40 GUSB 0.26 HMBS 5.20
UBC 0.249 GAPDH 0.229 UBC 0.41 POLR2A 0.30 UBC 5.29
RPLP0 0.264 UBC 0.237 RPLP0 0.43 ACTB 0.34 IPO8 5.62
HMBS 0.283 HMBS 0.309 HMBS 0.45 PGK1 0.34 RPLP0 8.24
B2M 0.300 B2M 0.321 B2M 0.46 IPO8 0.35 B2M 8.80
GUSB 0.314 GUSB 0.321 GUSB 0.47 HPRT1 0.39 GUSB 9.03
ACTB 0.341 ACTB 0.453 ACTB 0.56 RPLP0 0.42 ACTB 11.17
TFRC 0.371 YWHAZ 0.483 YWHAZ 0.59 TFRC 0.43 TFRC 13.49
YWHAZ 0.399 TFRC 0.495 TFRC 0.60 TBP 0.61 YWHAZ 13.73
TBP 0.439 TBP 0.647 TBP 0.72 YWHAZ 0.63 TBP 14.74
18S 0.490 18S 0.790 18S 0.85 18S 0.83 18S 16.00
RA SRnd/HF (n = 4/4) HMBS 0.134 PPIA 0.077 PPIA 0.34 HMBS 0.16 HMBS 1.41
PPIA 0.134 HMBS 0.126 HMBS 0.35 GAPDH 0.19 PPIA 1.50
POLR2A 0.211 RPLP0 0.168 POLR2A 0.36 UBC 0.20 POLR2A 3.83
GAPDH 0.230 POLR2A 0.173 RPLP0 0.37 PGK1 0.22 GAPDH 3.94
PGK1 0.240 B2M 0.198 GAPDH 0.37 PPIA 0.22 RPLP0 5.73
IPO8 0.247 GAPDH 0.211 B2M 0.38 POLR2A 0.24 PGK1 6.16
UBC 0.258 IPO8 0.221 IPO8 0.39 IPO8 0.26 IPO8 6.74
HPRT1 0.267 HPRT1 0.272 PGK1 0.41 18S 0.27 UBC 6.77
RPLP0 0.278 PGK1 0.288 HPRT1 0.42 GUSB 0.29 B2M 7.58
B2M 0.287 UBC 0.291 UBC 0.42 RPLP0 0.29 HPRT1 9.30
18S 0.298 18S 0.291 18S 0.43 B2M 0.31 18S 10.16
GUSB 0.316 GUSB 0.342 GUSB 0.46 ACTB 0.33 GUSB 11.17
ACTB 0.344 ACTB 0.464 ACTB 0.55 HPRT1 0.34 ACTB 12.74
YWHAZ 0.375 YWHAZ 0.501 YWHAZ 0.59 TBP 0.44 YWHAZ 14.24
TBP 0.407 TBP 0.546 TBP 0.63 YWHAZ 0.55 TBP 14.74
TFRC 0.451 TFRC 0.700 TFRC 0.76 TFRC 0.60 TFRC 16.00
RA/LA (n = 20/8) POLR2A 0.216 IPO8 0.185 IPO8 0.42 HMBS 0.21 IPO8 2.38
PPIA 0.216 HPRT1 0.227 GAPDH 0.44 PPIA 0.28 POLR2A 2.45
GAPDH 0.245 POLR2A 0.236 POLR2A 0.44 B2M 0.30 PPIA 2.51
IPO8 0.269 GAPDH 0.239 PPIA 0.44 POLR2A 0.31 GAPDH 3.31
HPRT1 0.288 PPIA 0.242 HPRT1 0.44 GAPDH 0.33 HPRT1 4.95
PGK1 0.310 RPLP0 0.270 GUSB 0.47 GUSB 0.37 HMBS 6.71
UBC 0.325 GUSB 0.273 PGK1 0.47 IPO8 0.41 GUSB 6.90
B2M 0.342 PGK1 0.281 RPLP0 0.48 UBC 0.41 B2M 7.00
GUSB 0.354 UBC 0.320 UBC 0.49 ACTB 0.42 PGK1 7.61
RPLP0 0.367 B2M 0.331 B2M 0.50 PGK1 0.47 UBC 7.94
YWHAZ 0.387 YWHAZ 0.410 YWHAZ 0.56 HPRT1 0.50 RPLP0 8.52
HMBS 0.409 ACTB 0.434 ACTB 0.58 RPLP0 0.50 ACTB 11.39
ACTB 0.429 HMBS 0.471 HMBS 0.59 TFRC 0.56 YWHAZ 11.68
TFRC 0.460 18S 0.570 18S 0.68 YWHAZ 0.61 TFRC 14.23
18S 0.487 TFRC 0.582 TFRC 0.69 18S 0.75 18S 14.49
TBP 0.534 TBP 0.787 TBP 0.86 TBP 0.83 TBP 16.00
RV/LV (n = 8/8) IPO8 0.233 GUSB 0.150 GUSB 0.47 POLR2A 0.27 GUSB 2.06
PGK1 0.233 YWHAZ 0.262 IPO8 0.50 HMBS 0.40 IPO8 2.71
HMBS 0.266 IPO8 0.267 PGK1 0.51 GUSB 0.45 PGK1 2.91
GAPDH 0.288 PGK1 0.308 YWHAZ 0.52 18S 0.47 HMBS 3.81
HPRT1 0.311 POLR2A 0.327 HMBS 0.53 GAPDH 0.47 POLR2A 3.96
GUSB 0.347 PPIA 0.334 HPRT1 0.54 B2M 0.53 YWHAZ 5.26
POLR2A 0.368 HMBS 0.339 POLR2A 0.55 IPO8 0.53 GAPDH 5.98
YWHAZ 0.393 HPRT1 0.351 GAPDH 0.56 PGK1 0.53 HPRT1 7.00
Continued
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Table 4 Continued
Genorm Normfinder Delta-Ct BestKeeper Consensus
Genes Stability value Genes Stability value Genes SD Genes SD Genes Geometric mean
of ranking values
18S 0.414 RPLP0 0.371 PPIA 0.56 PPIA 0.53 PPIA 8.30
UBC 0.432 GAPDH 0.373 RPLP0 0.58 HPRT1 0.54 18S 8.59
PPIA 0.455 18S 0.461 18S 0.62 UBC 0.56 RPLP0 10.89
RPLP0 0.470 UBC 0.484 UBC 0.63 YWHAZ 0.56 UBC 11.22
TFRC 0.499 TFRC 0.603 TFRC 0.73 RPLP0 0.65 B2M 11.77
B2M 0.534 B2M 0.627 B2M 0.76 ACTB 0.74 TFRC 13.69
TBP 0.566 TBP 0.665 TBP 0.78 TBP 0.76 TBP 15.00
ACTB 0.611 ACTB 0.838 ACTB 0.92 TFRC 0.83 ACTB 15.47
A/V (n = 28/16) HPRT1 0.302 POLR2A 0.264 HPRT1 0.52 POLR2A 0.31 POLR2A 1.68
PGK1 0.302 HPRT1 0.270 POLR2A 0.52 HMBS 0.35 HPRT1 2.11
GAPDH 0.309 PGK1 0.289 GAPDH 0.53 B2M 0.38 PGK1 3.22
POLR2A 0.351 GAPDH 0.294 PGK1 0.53 PPIA 0.39 GAPDH 3.66
IPO8 0.369 PPIA 0.297 PPIA 0.54 GAPDH 0.40 PPIA 5.32
UBC 0.391 RPLP0 0.307 IPO8 0.55 GUSB 0.43 HMBS 5.80
HMBS 0.413 IPO8 0.330 RPLP0 0.55 IPO8 0.45 IPO8 6.19
PPIA 0.428 UBC 0.408 UBC 0.60 UBC 0.48 UBC 7.44
RPLP0 0.447 HMBS 0.431 HMBS 0.61 PGK1 0.50 B2M 7.95
GUSB 0.471 GUSB 0.454 GUSB 0.63 HPRT1 0.53 RPLP0 8.21
B2M 0.488 B2M 0.467 B2M 0.64 ACTB 0.54 GUSB 8.80
YWHAZ 0.503 YWHAZ 0.473 YWHAZ 0.64 RPLP0 0.55 YWHAZ 12.24
18S 0.530 18S 0.561 18S 0.71 YWHAZ 0.60 ACTB 13.18
ACTB 0.558 ACTB 0.610 ACTB 0.75 18S 0.67 18S 13.24
TFRC 0.592 TFRC 0.731 TFRC 0.84 TFRC 0.77 TFRC 15.00
TBP 0.625 TBP 0.744 TBP 0.85 TBP 0.81 TBP 16.00
RV CT/HF (n = 4/4) GAPDH 0.185 GUSB 0.176 GAPDH 0.47 POLR2A 0.28 GAPDH 1.97
HPRT1 0.185 PPIA 0.195 GUSB 0.49 HPRT1 0.38 POLR2A 3.13
HMBS 0.203 GAPDH 0.211 PPIA 0.50 UBC 0.38 GUSB 3.22
PGK1 0.226 POLR2A 0.252 POLR2A 0.51 HMBS 0.39 HPRT1 3.25
IPO8 0.239 RPLP0 0.274 PGK1 0.52 GAPDH 0.42 PPIA 4.53
POLR2A 0.270 IPO8 0.312 IPO8 0.52 GUSB 0.50 HMBS 5.73
UBC 0.304 PGK1 0.329 HPRT1 0.52 PPIA 0.53 PGK1 6.12
18S 0.329 HPRT1 0.347 RPLP0 0.53 18S 0.54 IPO8 6.34
GUSB 0.362 YWHAZ 0.360 HMBS 0.54 IPO8 0.55 UBC 7.10
PPIA 0.389 HMBS 0.367 YWHAZ 0.58 PGK1 0.58 RPLP0 8.52
RPLP0 0.411 UBC 0.471 UBC 0.62 B2M 0.60 18S 9.80
YWHAZ 0.434 18S 0.555 18S 0.67 RPLP0 0.62 YWHAZ 10.89
TFRC 0.475 TFRC 0.679 TFRC 0.80 YWHAZ 0.73 TFRC 13.24
TBP 0.525 TBP 0.715 TBP 0.82 TFRC 0.82 B2M 13.88
B2M 0.573 B2M 0.771 B2M 0.88 ACTB 0.85 TBP 14.48
ACTB 0.623 ACTB 0.889 ACTB 0.97 TBP 0.93 ACTB 15.74
LV CT/HF (n = 4/4) GUSB 0.169 YWHAZ 0.089 YWHAZ 0.45 POLR2A 0.19 YWHAZ 1.19
YWHAZ 0.169 GUSB 0.129 GUSB 0.45 HMBS 0.38 GUSB 2.00
IPO8 0.223 IPO8 0.206 IPO8 0.46 YWHAZ 0.38 IPO8 3.71
PGK1 0.257 PGK1 0.307 PGK1 0.51 GUSB 0.39 PGK1 4.23
HMBS 0.289 HMBS 0.334 HMBS 0.53 18S 0.41 HMBS 4.40
18S 0.323 18S 0.361 18S 0.55 IPO8 0.41 POLR2A 4.74
POLR2A 0.349 HPRT1 0.379 HPRT1 0.56 PGK1 0.41 18S 6.00
B2M 0.377 POLR2A 0.408 B2M 0.58 B2M 0.47 B2M 8.24
GAPDH 0.405 B2M 0.411 POLR2A 0.58 GAPDH 0.47 HPRT1 8.76
HPRT1 0.424 PPIA 0.441 GAPDH 0.62 PPIA 0.52 GAPDH 9.93
UBC 0.448 RPLP0 0.469 PPIA 0.62 TBP 0.60 PPIA 10.94
RPLP0 0.479 GAPDH 0.484 RPLP0 0.63 HPRT1 0.62 RPLP0 12.42
PPIA 0.501 UBC 0.517 UBC 0.66 ACTB 0.66 UBC 12.70
Continued
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Table 4 Continued
Genorm Normfinder Delta-Ct BestKeeper Consensus
Genes Stability value Genes Stability value Genes SD Genes SD Genes Geometric mean
of ranking values
TFRC 0.522 TFRC 0.545 TFRC 0.69 UBC 0.67 TBP 13.88
TBP 0.550 TBP 0.628 TBP 0.74 RPLP0 0.69 TFRC 14.48
ACTB 0.597 ACTB 0.844 ACTB 0.93 TFRC 0.79 ACTB 15.19
A, atrium; V, ventricle; RA, right atrium; LA, left atrium; RV, right ventricle and LV, left ventricle. SR, sinus rhythm, SRnd, sinus rhythm without atrium dilatation; SRd, sinus rhythm
with atrium dilatation; AF, atrial fibrillation; pAF, paroxysmal atrial fibrillation; cAF, permanent atrial fibrillation; HF, heart failure; CT, healthy controls.
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Figure 3 Relative quantification of PPP2CA and ADCY5 expression in normal and diseased right atrial and ventricle samples, respectively. Plot of the mean ±
SEM gene expression ratio of PPP2CA and ADCY5 normalized to 18S (A, C), or to the set of 5 reference genes (GAPDH, IPO8, POLR2A, PPIA, and YWHAZ) (B, D)
to illustrate the variability in PPP2CA and ADCY5 expression in different heart diseases depending on the selection of the reference gene. SRnd, atrial samples
from patients in sinus rhythm without atria dilatation; SRd, atrial samples from patients in sinus rhythm with atria dilatation; pAF, atrial samples from patients
with paroxysmal atrial fibrillation; cAF, atrial samples from patients with chronic atrial fibrillation; CT, right ventricle samples from healthy controls; HF, right
ventricle samples from patients with heart failure. *P <_ 0.05 for comparisons as indicated.
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